In liver cancer, the use of curcumin (NF-kB signaling pathway inhibitor) to block NF-kB can specifically target the CSC population, and suggests the potential for the combined inhibition of NF-kB and HDAC signals can be used to treat patients with poor prognosis [126]. This evidence concerns the gene NFKB1 and liver cancer.